Arrowhead third-one fourth 2010 net loss decreases to $0.

This compares with a net lack of $2.5 million, or $0.6 per share predicated on 43.4 million weighted average shares outstanding, june 30 for the quarter ended, 2009. In addition to the change in revenue and operating expenses, a non-cash gain of $1.6 million was recorded as the change in value of a derivative liability.. Arrowhead third-one fourth 2010 net loss decreases to $0.4 million Arrowhead Research Corporation today announced financial results for its fiscal 2010 third quarter ended June 30, 2010. In the third one fourth, we continued to progress our late-stage subsidiaries and build on the momentum we began early in the calendar year, said Christopher Anzalone, Arrowhead’s CEO.If you lived here or there, in the event that you smoked, it proved helpful, Ridker said. AstraZeneca paid for the study, and Ridker and other authors possess consulted for the ongoing business and other statin makers. One concern: More people in the Crestor group noticed blood-sugar levels rise or were recently diagnosed with diabetes. Crestor also has the highest rate among statins of a rare but serious muscle issue, so there are safer and cheaper methods for getting the same benefits probably, said Dr. Sidney Wolfe of the consumer group Public Citizen.